Centessa Pharmaceuticals Future Growth

Future criteria checks 0/6

Centessa Pharmaceuticals is forecast to grow earnings and revenue by 10.2% and 66.2% per annum respectively. EPS is expected to grow by 18.6% per annum. Return on equity is forecast to be -96.7% in 3 years.

Key information

10.2%

Earnings growth rate

18.6%

EPS growth rate

Biotechs earnings growth	42.4%
Revenue growth rate	66.2%
Future return on equity	-96.7%
Analyst coverage	Low
Last updated	14 Aug 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

MUN:260 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	36	-198	-178	N/A	4
12/31/2025	N/A	-198	-169	-176	5
12/31/2024	N/A	-185	-165	-160	5
6/30/2024	7	-157	-146	-146	N/A
3/31/2024	7	-138	-150	-150	N/A
12/31/2023	7	-151	-161	-160	N/A
9/30/2023	N/A	-157	-182	-181	N/A
6/30/2023	N/A	-173	-183	-183	N/A
3/31/2023	N/A	-212	-199	-198	N/A
12/31/2022	N/A	-216	-202	-201	N/A
9/30/2022	N/A	-234	-201	-205	N/A
6/30/2022	N/A	-220	-195	-199	N/A
3/31/2022	N/A	-197	-169	-173	N/A
12/31/2021	N/A	-381	-136	-136	N/A
9/30/2021	N/A	-324	-88	-83	N/A
6/30/2021	N/A	-286	-56	-52	N/A
3/31/2021	N/A	-246	-24	-20	N/A
12/31/2020	N/A	-11	-11	-11	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 260 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 260 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 260 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 260 is forecast to have no revenue next year.

High Growth Revenue: 260 is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 260 is forecast to be unprofitable in 3 years.

Centessa Pharmaceuticals Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Centessa Pharmaceuticals Initiates Phase 2 Trial with ORX750, a Novel Orexin Receptor 2 (OX2R) Agonist

Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $150 million.

Centessa Pharmaceuticals plc Announces Positive Interim Phase 1 Clinical Data with Its Novel Orexin Receptor 2 (OX2R) Agonist, Orx750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals plc Announces Chief Financial Officer Changes

Insufficient new directors

Centessa Pharmaceuticals plc has completed a Follow-on Equity Offering in the amount of $99.999993 million.

Centessa Pharmaceuticals plc has filed a Follow-on Equity Offering in the amount of $100 million.

Centessa Pharmaceuticals plc Announces Open IND for ORX750

Centessa Pharmaceuticals plc Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2A Study of Serpinpc for the Treatment of Hemophilia

Centessa Pharmaceuticals plc Announces Dosing of First Subject in Registrational Present-3 Study Evaluating Serpinpc for the Treatment of Hemophilia B with Inhibitors

Centessa Pharmaceuticals plc Announces Preclinical Data Supporting Orx750's Potential as A Best-In-Class Oral Ox2r Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders

World Sleep Congress Releases an Abstract Submit by Centessa Pharmaceuticals plc

Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B Without Inhibitors

High number of new and inexperienced directors

Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for Serpinpc for Hemophilia B

Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors

High number of new and inexperienced directors

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies